🔴 Alzamend Neuro is trading 6.47% down in after-hours trading after filing a quarterly report raising going-concern doubts

Alzamend Neuro is trading 6.47% down at $1.59 in after-hours trading after filing its September 10, 2026 Form 10-Q for the quarter ended July 31, 2026.

• The report disclosed a $3.027 million net loss, no product revenue, and substantial doubt about the company’s ability to continue as a going concern.
• It highlighted dependence on additional financing, potential dilution from convertible preferred stock, higher expenses, and a delayed Alzheimer’s program.